AI-Powered Software Urinary Cytology for Bladder Cancer
Early detection is crucial, as it significantly improves treatment outcomes and survival rates, making awareness and proactive screening essential.
Go to Video
Bladder Cancer Facts
A bladder cancer diagnosis can be devastating.
And this cancer is more common than many may realize.
4TH(1)
Most common cancer in men
16.8K(2)
Estimated U.S.
deaths
83.2K(2)
Estimated new
U.S cases
77%(3)
High-grade 10-year recurrence rate
$9.4B(4)
Estimated national expenditure for bladder cancer care
Some bladder cancers are prone to recurrence and progression
Long-term surveillance is necessary
Invasive cystoscopies can cause pain, anxiety, and treatment delays
High treatment costs over lifetime
AIxURO: Revolutionizing Urine Cytology for Enhanced Bladder Cancer Detection
AIxURO is revolutionizing bladder cancer diagnostics by enhancing traditional urine cytology analysis. By leveraging advanced artificial intelligence technology, AIxURO, in research studies, has been shown to significantly improve the accuracy and efficiency of urine evaluations. This innovative approach allows for more precise identification of cancerous cells, which is crucial for timely diagnosis and treatment.
User-Friendly Software
  • The AIxMED Cytology Viewer is intuitive and simple to navigate
  • Uses The Paris System (TPS) for Reporting Urinary Cytology
AIxURO: The Alliance of Morphology, Statistics, and AI
  • Atypical (AUC) & suspicious (SHGUC/HGUC) cells analyzed and presented in an easy to view gallery
  • Easy to read graphs and calculations
  • Easy to read graphs and quantitative statistics
  •  Morphology icons highlight  TPS criteria
Leverage AI for Diagnostic Confidence
  • AIxURO uses advanced algorithms to assist in cancer cell detection
  • AIxURO combines WSI, qualitative morphology & quantitative metrics to improve accuracy in diagnostics
Seamless and Efficient
  • Eliminate need to transfer glass slides
  • AI-prescreening to select abnormal cells
  • Rapid diagnosis for large workloads with 50-80% reduction in review time
Integration and Implementation Flexibility
  • AIxURO software is compatible with most commonly used digital scanners
  • Open platform accepts .tiff, .svs, jpeg files and outputs small file sizes to maximize storage space
  • Compatible with existing liquid-based preparation methods
  • LIS interface capability available
Why choose AIxURO
AIxURO accurately identifies suspicious and atypical cells using a non-invasive urine sample.
Book demo
1st commercial
application
Currently available for Research Use Only (RUO) in the United States
Quantitative scoring of samples using The Paris System (TPS)
Ideal for use with exfoliative, voided samples
Reduces the need for frequent cystoscopies
Improves patient compliance
with treatment plans
Reduces healthcare costs
through fewer procedures
Where AIxURO Aids the Bladder Cancer Patient Journey
Qualitative and quantitative data derived from our Al-powered AlxURO computational platform, can positively impact your workflows and patient journeys. Experience the difference!
Bladder Cancer Signs and Symptoms
Urology Consultation

Specimen Collection and Processing

  1. Noninvasive, voided urine collection
  2. Processed with standard liquid based prep methods by the laboratory

Diagnosis and Prediction

  1. High-resolution images of the stained slides are captured
  2. Urine cytology with AI assistance to enhance detection of bladder cancer cells or precursors
Surgical Assistance

Post-Treatment Follow Up

Repeat voided urines with AI assisted detection of recurrent tumor

Other Applications
For Thyroid Cytology:
Thyroid Cancer
Coming soon
AIxTHY: Revolutionizing thyroid cancer detection and diagnosis.
Coming soon
For Cervical Cytology:
Cervical Cancer
Coming soon
AIxPAP: Cervical cancer is preventable but remains a major health challenge.
Coming soon
For Pulmonary Cytology:
Lung Cancer
Coming soon
AIxPUL: Empowering precision in lung cancer detection.
Coming soon
1. American Cancer Society (ACS) Cancer, Facts & Figures 2024, Slide Set: Cancer Facts & Figures 2024, accessed 2024.
2. SEER Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda, MD, accessed 2024.
3. Wan H, Zhan X, Li X, et al. Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer. BMC Urol. 2023;23(1):182. Published 2023 Nov 10. doi: 10.1186/s12894-023-01342-2
4. Cancer Trends Progress Report, National Cancer Institute, Bethesda, MD, accessed 2024.